Windlas Biotech Limited has informed the Exchange about Investor Presentation

Windlas Biotech reported FY26 revenue of Rs 904 Cr, up 19% YoY, with Q4 revenue of Rs 238 Cr marking the 13th consecutive quarter of record revenue. Adjusted EBITDA grew 26% to Rs 121 Cr (13.4% margin) and adjusted PAT rose 31% to Rs 83 Cr (9.2% margin), with EPS at Rs 31.60. The company is net debt free with Rs 251 Cr strong net liquidity and generated Rs 105 Cr operating cash flow. CDMO vertical contributed Rs 664 Cr (73% of revenue, +20%), Trade Generics contributed Rs 195 Cr (22%, +13%), and Exports grew 40% to Rs 46 Cr. Plant-6 has achieved mechanical completion and is on track for commercialization by H1 FY27. The company completed a Rs 47 Cr buyback (without promoter participation) and proposed dividend of Rs 13 Cr (Rs 6.30/share).